[1] Birnkrant DJ, Ararat E, Mhanna MJ. Cardiac phenotype determines survival in Duchenne muscular dystrophy [J]. Pediatr Pulmonol, 2016, 51(1): 70-76.
[2] Mah JK, Korngut L, Dykeman J, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy [J]. Neuromuscul Disord, 2014, 24(6): 482-491.
[3] Nigro G, Comi LI, Politano L, et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy [J]. Int J Cardiol, 1990, 26(3): 271-277.
[4] Viollet L, Thrush PT, Flanigan KM, et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy [J]. Am J Cardiol, 2012, 110(1): 98-102.
[5] Spurney C, Shimizu R, Morgenroth LP, et al. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy [J]. Muscle Nerve, 2014, 50(2): 250-256.
[6] Ho R, Nguyen ML, Mather P. Cardiomyopathy in Becker muscular dystrophy: Overview [J]. World J Cardiol, 2016, 8(6): 356-361.
[7] Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care [J]. Lancet Neurol, 2010, 9(2): 177-189.
[8] Hoogerwaard EM, van der Wouw PA, Wilde AA, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy [J]. Neuromuscul Disord, 1999, 9(5): 347-351.
[9] Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study [J]. Lancet, 1999, 353(353): 2116-2119.
[10] Florian AR, Ludwig A, Rösch S, et al. Differences in cardiac involvement between carriers of Duchenne and Becker muscular dystrophy–a cardiovascular magnetic resonance study [J]. J Cardiovasc Magn Reson, 2015, 17(1): 1-2.
[11] Nakamura A. X-Linked dilated cardiomyopathy: a cardiospecific phenotype of dystrophinopathy [J]. Pharmaceuticals (Basel), 2015, 8(2): 303-320.
[12] Berko BA, Swift M. X-linked dilated cardiomyopathy [J]. N Engl J Med, 1987, 316(19): 1186-1191.
[13] Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus [J]. Circulation, 1993, 87(6): 1854-1865.
[14] Castro-Gago M, Gómez-Lado C, Eirís-Puñal J. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients [J]. Brain Dev, 2009, 31(2): 184.
[15] 田淑芬. 假性肥大型肌营养不良儿童血清脑利钠肽水平与心脏功能的相关性[J]. 武汉大学学报(医学版), 2011, 32(2): 219-221.
[16] Mohyuddin T, Jacobs IB, Bahler RC. B-type natriuretic peptide and cardiac dysfunction in Duchenne muscular dystrophy [J]. Int J Cardiol, 2007, 119(3): 389-391.
[17] Thrush PT, Edward N, Flanigan KM, et al. Precordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy [J]. Congenit Heart Dis, 2013, 8(6): 561-567.
[18] Chiang DY, Allen HD, Kim JJ, et al. Relation of cardiac dysfunction to rhythm abnormalities in patients with Duchenne or Becker muscular dystrophies [J]. Am J Cardiol, 2016, 117(8): 1349-1354.
[19] Villa CR, Czosek RJ, Ahmed H, et al. Ambulatory monitoring and arrhythmic outcomes in pediatric and adolescent patients with Duchenne muscular dystrophy [J]. J Am Heart Assoc, 2015, 5(1): e002620.
[20] Ashwath ML, Jacobs IB, Crowe CA, et al. Left ventricular dysfunction in Duchenne muscular dystrophy and genotype [J]. Am J Cardiol, 2014, 114(2): 284-289.
[21] Yamamoto T, Tanaka H, Matsumoto K, et al. Utility of transmural myocardial strain profile for prediction of early left ventricular dysfunction in patients with Duchenne muscular dystrophy [J]. Am J Cardiol, 2013, 111(6): 902-907.
[22] Mori K, Hayabuchi Y, Inoue M, et al. Myocardial strain imaging for early detection of cardiac involvement in patients with Duchenne's progressive muscular dystrophy [J]. Echocardiography, 2007, 24(6): 598-608.
[23] Takano H, Fujii Y, Yugeta N, et al. Assessment of left ventricular regional function in affected and carrier dogs with Duchenne muscular dystrophy using speckle tracking echocardiography [J]. BMC Cardiovasc Disord, 2011, 11: 23.
[24] Kansal MM, Panse PM, Abe H, et al. Relationship of contrast-enhanced magnetic resonance imaging-derived intramural scar distribution and speckle tracking echocardiography-derived left ventricular two-dimensional strains [J]. Eur Heart J Cardiovasc Imaging, 2012, 13(2): 152-158.
[25] Hickey RM, Cullen JD, Sachs GM. An overview of cardiac management in neuromuscular disease [J]. Open Cardiovasc Med J, 2016, 10: 82-88.
[26] Silva MC, Meira ZM, Gurgel GJ, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy [J]. J Am Coll Cardiol, 2007, 49(18): 1874-1879.
[27] Verhaert D, Richards K, Rafael-Fortney JA, et al. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations [J]. Circ Cardiovasc Imaging, 2011, 4(1): 67-76.
[28] Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach [J]. J Cardiovasc Magn Reson, 2008, 10: 50.
[29] Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function [J]. J Cardiovasc Magn Reson, 2013, 15: 107.
[30] Turkbey EB, Gai N, Lima JA, et al. Assessment of cardiac involvement in myotonic muscular dystrophy by T1 mapping on magnetic resonance imaging [J]. Heart Rhythm, 2012, 9(10): 1691-1697.
[31] Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy [J]. J Am Coll Cardiol, 2005, 45(6): 855-857.
[32] Allen HD, Flanigan KM, Thrush PT, et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy [J]. PLoS Curr, 2013, 5.pii: ecurrents.md.2cc69a1dae4be7dfe2bcb420024ea865.
[33] Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial [J]. JAMA, 2007, 298(10): 1171-1179.
[34] Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial [J]. Lancet Neurol, 2015, 14(2): 153-161.
[35] Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy [J]. Neurology, 2011, 77(5): 444-452.
[36] Dec GW. Steroid therapy effectively delays Duchenne's cardiomyopathy [J]. J Am Coll Cardiol, 2013, 61(9): 955-956.
[37] Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy [J]. J Pediatr, 2013, 163(4): 1080-1084.
[38] Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy [J]. J Am Coll Cardiol, 2013, 61(9): 948-954.
[39] Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy [J]. N Engl J Med, 2011, 364(16): 1513-1522.
[40] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity [J]. Science, 2012, 337(6096): 816-821.
[41] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems [J]. Science, 2013, 339(6121): 819-823.
[42] Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy [J]. Science, 2016, 351(6271): 403-407.
[43] Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients [J]. J Heart Lung Transplant, 2010, 29(4): 432-438.
